MedTrace Logo

HILT in Greater Trochanteric Pain Syndrome

NCT07749066 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-08-06

No results posted yet for this study

Summary

Greater Trochanteric Pain Syndrome (GTPS) is a common cause of lateral hip pain that can significantly impair daily activities and quality of life. Conservative treatments, including physical therapy modalities and injections, are considered first-line management.

High-Intensity Laser Therapy (HILT) is a non-invasive modality with greater tissue penetration compared to low-level laser therapy and has shown promising results in musculoskeletal disorders; however, evidence in GTPS is limited.

This study aims to evaluate the efficacy of HILT compared with a sham intervention in patients with GTPS, focusing on pain intensity, functional status, and quality of life.

Conditions

  • Greater Trochanteric Pain Syndrome

Interventions

DEVICE

High-Intensity Laser Therapy (HILT)

High-intensity laser therapy will be applied to the trochanteric region using a pulsed Nd:YAG laser device over 10 sessions (5 sessions per week for 2 consecutive weeks). Treatments will be delivered by an experienced physiotherapist using a standardized protocol and consistent application technique. Total energy per session will be standardized. Participants will also perform a structured home exercise program focusing on hip muscle activation and flexibility.

DEVICE

Sham Laser

A sham laser intervention will be applied using the same device and treatment setup without delivering therapeutic laser energy. The number and frequency of sessions will be identical to the active treatment group to ensure blinding. Participants will also perform the same structured home exercise program as the intervention group.

Sponsors & Collaborators

  • Ankara Etlik City Hospital

    lead OTHER_GOV

Principal Investigators

  • Gizem Suna Tuncer, MD, Specialist Physician · Ankara Etlik City Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-06-30
Completion
2027-07-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07749066 on ClinicalTrials.gov